The United Laboratories International Holdings Limited provided consolidated earnings guidance for the six months ended June 30, 2014. For the period, the company expected to record a substantial increase to a profit of not less than HKD 650,000,000, while the profit for the six months ended June 30, 2013 is HKD 42,992,000. The increase in profit is mainly attributable to the overall gross profit was improved due to increase in selling prices of intermediate and bulk medicine products, and decrease in production costs through new production capacity being steadily released and the production technology of enzymatic bulk amoxicillin being mature of the Inner Mongolian's plant; and in light of the cessation of operations of the Chengdu production plant last year, a subsidy income from the government of approximately HKD 390,000,000 was received during the period.